Two student dormitories in Wiener Neustadt have entered insolvency proceedings, according to reports from local media. The Campus Residence Ungargasse GmbH and the Campus Residence Grünangergasse GmbH have each filed for restructuring without self-administration with the district court in Wiener Neustadt. The liabilities of both entities exceed ten million euros combined, affecting 13 and 10 creditors respectively, along with five employees. Operations are planned to continue under new conditions. The properties in question are located near the city campus of the FH Wiener Neustadt. The Ungargasse 9 property offers 67 units, with liabilities around six million euros. The Grünangergasse property has 62 units, with liabilities approximately four point five million euros. The insolvency was attributed to rising energy, operational, and financing costs that could not be fully passed on to tenants. To increase occupancy rates, more short-term rentals were offered recently, which led to a drop in pricing levels. Legal disputes with tenants are ongoing. Renting to students will be suspended, and future operations will focus exclusively on short-term rentals. Credit protectors offer creditors a quota of 20 percent, payable within two years after acceptance of the restructuring plan. This shift aims to stabilize cash flow while addressing the financial strain caused by increased expenses. Separately, another company, Marinomed Biotech AG, based in Korneuburg, has also declared insolvency. The firm, listed on the Vienna Stock Exchange's Prime Market, has applied for restructuring without self-administration before the district court in Korneuburg. Payments have been halted, confirmed by KSV1870. Thirty employees are affected, though wages and salaries were paid up until June 2026. Founded in 2006 as a spin-off from the University of Veterinary Medicine Vienna, Marinomed develops treatments for viral respiratory infections and products in immunology. It ventured onto the stock market in 2019, offering over-the-counter remedies for colds, allergen-blocking nasal sprays, and eye drops. This marks its second insolvency in quick succession. A restructuring process was previously attempted in 2024, which was revoked due to unmet earn-out payments, making the plan unfulfillable. Marinomed’s liabilities amount to roughly 27.9 million euros, of which 21.8 million are deemed uncertain. Around 90 creditors are involved. The company holds intellectual property in the form of patents and trademarks, as well as a business premises in Korneuburg. Additional claims arise from the sale of the carrageenan business, whose economic viability is crucial for the proceeding’s progression, according to AKV. Despite the challenging situation, Marinomed seeks continuation. Creditors are being offered a restructuring plan quota of 20 percent within two years. Alexander Greifeneder from KSV1870 notes this is initially the legal minimum. The insolvency administrator must assess whether continued operation is economically viable and if the restructuring plan can be fulfilled.
4 reports
KurierParty-alignedCenterFactual 70Objective 75yesterdayThe Austrian biotechnology company Marinomed Biotech AG has filed for insolvency again, marking its second bankruptcy within a short period. Based in Korneuburg, the firm was listed on Vienna’s Prime Market and had previously undergone a restructuring process in 2024, which failed due to unfulfilled earn-out payments. The company now owes approximately 27.9 million euros, with 21.8 million euros considered unsecured. Around 90 creditors are affected, including employees whose salaries were paid up to June 2026. Marinomed proposes a 20 percent repayment plan for creditors over two years, though this remains under review by the insolvency administrator.
Bias read (Center): The article reports on the financial failure of a private biotech company without taking a stance on political issues, policies, or figures. It focuses on economic outcomes and corporate actions, presenting facts without ideological framing.
Why factuality (70): This article provides detailed information about Marinomed's financial state, including debt figures, the number of creditors, and the specifics of the restructuring plan. It matches the other sources but lacks some contextual background compared to the first article.
Why objectivity (75): The article maintains a neutral tone overall, though it includes specific details about the financial situation that might be seen as more informative than purely objective reporting.
oe24IndependentCenterFactual 50Objective 602 days agoThe article reports that a chocolate manufacturer, which has been in operation for 100 years, has gone bankrupt. The headline highlights the historical significance of the company's longevity before its financial collapse. The piece likely discusses the reasons behind the insolvency, such as market challenges, economic pressures, or operational difficulties. It may also touch on the impact of the bankruptcy on employees, suppliers, and the local economy. No specific details about the cause of insolvency or any ongoing legal proceedings are provided.
Bias read (Center): The article presents a factual report on the insolvency of a long-standing chocolate manufacturer without overtly favoring any political stance. While the event itself could have broader economic implications, the tone and framing remain neutral, focusing on the business aspect rather than taking a党
Why factuality (50): This article appears to be about a different event entirely – the insolvency of a chocolate manufacturer after 100 years. It does not relate to Marinomed or the other articles, making it inconsistent with the cross-source consensus.
Why objectivity (60): The article is presented in a straightforward manner, but since it covers a completely unrelated topic, it fails to maintain objectivity within the context of the shared event being discussed.
oe24IndependentCenterFactual 45Objective 653 days ago 7 million euros in debt: paint specialist goes bankruptA specialist in car painting has gone bankrupt with debts amounting to seven million euros. The company, which was known for its expertise in automotive coatings, faced financial difficulties that ultimately led to its insolvency. This development has significant implications for employees, clients, and suppliers who now face uncertainty regarding outstanding payments and contracts. The bankruptcy highlights challenges within the specialized automotive repair industry, particularly in managing large-scale debt.
Bias read (Center): The article reports on a business bankruptcy without apparent political commentary or bias. It focuses on economic implications rather than political decisions or ideologies.
Why factuality (45): This article states that a "Lackier-Spezialist" (painting specialist) has incurred 7 million euros in debt and is sliding into bankruptcy. Again, no primary source is available for verification, and the article lacks detailed information about the company, industry, or background. The discrepancy be
Why objectivity (65): The language is factual and objective, presenting the situation as a business challenge without apparent bias. The phrase "schlittert in die Pleite" (sliding into bankruptcy) is descriptive rather than judgmental, maintaining a neutral tone.
KurierParty-alignedCenter7 hr. ago Varta before the out: creditors want to break up corporationsThe Austrian battery manufacturer Varta faces potential dissolution after losing the support of its main financiers. Just one year after a restructuring agreement, the company is now at risk of being split up due to severe financial difficulties. Key creditors, including Deutsche Bank and several investment firms, have called for the separation of the household battery division from the rest of the company. According to an independent analysis by FTI Consulting, Varta lacks tens of millions of euros in liquidity needed to cover operational costs such as paying suppliers, salaries, and maintaining machinery. Additionally, significant capital is required to sustain operations long-term. Michael Tojner, an Austrian investor and shareholder in Varta through his firm MT-Invest, expressed disappointment over the decision but acknowledged the challenges facing the European battery industry compared to Asia. He stated that MT-Invest plans to separate the microbattery and solutions divisions from the restructuring process to preserve European battery production expertise.
Bias read (Center): The article presents the situation objectively, quoting both the creditors' demands and the response from Michael Tojner, highlighting the financial challenges faced by Varta without overtly favoring any side. The framing remains neutral, focusing on the economic and structural issues rather than a
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
Austria
